Perspective Therapeutics, Inc.
Initiate dosing in PSV359 clinical program
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 3 Feb 2025
- Due
- 30 Jun 2025
- Delivered
- 29 Apr 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“PSV359 (FAP-α) Multiple solid tumors IND filed in late 2024 Expect to initiate dosing in mid-2025”
What we found
Evidence strength B What the grades mean
Perspective Therapeutics announced the first patient was dosed with PSV359 on April 29, 2025, ahead of its mid-2025 target.
-
B PSV359 Program Company pipeline page states first patient dosed in April 2025
-
B Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors Company press release confirming first patient dosed with PSV359
Checked 12 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Language
- Expected (“expects”, “plans”)
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Perspective Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-CATX-000080 · Corrections policy